Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. - Gordon,L.I.; Molina,A.; Witzig,T.; Emmanouilides,C.; Raubtischek,A.; Darif,M.; Schilder,R.J.; Wiseman,G.; White,C.A. (Blood, 2004)